Implications of single-cell immune landscape of tumor microenvironment for the colorectal cancer diagnostics and therapy

Med Oncol. 2023 Nov 11;40(12):352. doi: 10.1007/s12032-023-02226-z.

Abstract

Colorectal cancer (CRC) originates from the polyps lining the colon and is among the most common types of cancer. With the increasing popularity of single-cell sequencing technologies, researchers have been able to better understand the immune landscape of colorectal cancer, by analyzing their expression and interactions in detail with the tumor microenvironment (TME) at single-cell level. Since the tumor-immune cell interactions play a critical part in the advancement as well as treatment response in colorectal cancer, the release of inhibitory factors such as T cells are important for recognizing and destroying cancer cells. Such information is vital to identify immunotherapeutic targets for cure and monitoring response to treatments. Therefore, a comprehensive single-cell studies-based overview of key immunogenic agents regulating the TME of CRC is provided in this review. Tumor-associated macrophages can promote tumor growth and resistance to treatment by releasing factors that inhibit the function of other immune cells. Additionally, colorectal cancer cells can express programmed cell death protein 1 and its ligand, which can also inhibit T-cell function. Researchers have found that certain types of immune cells, prominently T cells, natural killer, and dendritic cells, can have a positive impact on the prognosis of colorectal cancer patients. Treatments like immune checkpoint inhibitors and CAR-T therapies that help to release the inhibitory signals from the cancer cells allow the immune cells to function more effectively.

Keywords: B cells; Colorectal cancer; Macrophages; NK cells; Single-cell RNA-seq; T cells; TME.

Publication types

  • Review

MeSH terms

  • Cell Communication
  • Colorectal Neoplasms* / diagnosis
  • Colorectal Neoplasms* / therapy
  • Humans
  • Immune Checkpoint Inhibitors
  • Immunotherapy, Adoptive
  • Tumor Microenvironment*

Substances

  • Immune Checkpoint Inhibitors